Tiziana Life Sciences Forum

Beaufort Securities's note out this morning on Research Tree: "Tiziana progressed well during the FY2015. It strengthened its portfolio by acquiring exclusive licence for both milciclib and foralumab which brings the Group two research projects and two clinical programmes together plus research into a cancer stem cell diagnostic. Group’s successful fund raisings during the period demonstrated Board’s confidence as well as shareholders’ continuing support. Post the period, the Group raised a further £709,406 through the issue of unsecured convertible loan notes to existing shareholders, further expanded its highly experienced clinical development team and announced plans for additional development of foralumab in two clinical indications: i) graft vs host disease, and ii) ulcerative colitis. Moreover, the research agreement with Cardiff University has led to the identification of lead clinical candidate, CB1, a Bcl-3 inhibitor with potent anti-metastatic activity and impressive in-vivo efficacy and safety profile. An Investigational New Drug Application for CB1 will be filed in 2016, with clinical trials expected to begin before the year end. The strengthened balance sheet will support Tiziana to progress its existing and new clinical trials and give Group the resources to expand its presence internationally. We are encouraged by the Group’s performance last year and the commitment by existing investors."

Welcome to the new Tiziana Life Sciences stream forum! Messages posted in the Tiziana Life Sciences stream will be logged here for posterity.